363 related articles for article (PubMed ID: 23571146)
1. Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Engelen SM; Maas M; Lahaye MJ; Leijtens JW; van Berlo CL; Jansen RL; Breukink SO; Dejong CH; van de Velde CJ; Beets-Tan RG; Beets GL
Eur J Cancer; 2013 Jul; 49(10):2311-20. PubMed ID: 23571146
[TBL] [Abstract][Full Text] [Related]
2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
4. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
[TBL] [Abstract][Full Text] [Related]
5. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
Strassburg J; Ruppert R; Ptok H; Maurer C; Junginger T; Merkel S; Hermanek P
Ann Surg Oncol; 2011 Oct; 18(10):2790-9. PubMed ID: 21509631
[TBL] [Abstract][Full Text] [Related]
6. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.
Taylor FG; Quirke P; Heald RJ; Moran BJ; Blomqvist L; Swift IR; Sebag-Montefiore D; Tekkis P; Brown G;
J Clin Oncol; 2014 Jan; 32(1):34-43. PubMed ID: 24276776
[TBL] [Abstract][Full Text] [Related]
7. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
9. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
[TBL] [Abstract][Full Text] [Related]
10. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
11. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
[TBL] [Abstract][Full Text] [Related]
12. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
14. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E
Dis Colon Rectum; 2015 Jun; 58(6):556-65. PubMed ID: 25944427
[TBL] [Abstract][Full Text] [Related]
15. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
16. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
17. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
Lombardi R; Cuicchi D; Pinto C; Di Fabio F; Iacopino B; Neri S; Tardio ML; Ceccarelli C; Lecce F; Ugolini G; Pini S; Di Tullio P; Taffurelli M; Minni F; Martoni A; Cola B
Ann Surg Oncol; 2010 Mar; 17(3):838-45. PubMed ID: 20012700
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Kim CW; Yu CS; Yang SS; Kim KH; Yoon YS; Yoon SN; Lim SB; Kim JC
Ann Surg Oncol; 2011 Nov; 18(12):3271-7. PubMed ID: 21537868
[TBL] [Abstract][Full Text] [Related]
19. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
Doornebosch PG; Ferenschild FT; de Wilt JH; Dawson I; Tetteroo GW; de Graaf EJ
Dis Colon Rectum; 2010 Sep; 53(9):1234-9. PubMed ID: 20706065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
